Paraskevi Tsiolaki

Dr. Paraskevi Tsiolaki

University of California San Francisco
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KBKonstantina V. Biza
Konstantina V. Biza
KNKaterina Nastou
Katerina Nastou
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
CMChara V. Mastrokalou
Chara V. Mastrokalou
SHStavros J. Hamodrakas
Stavros J. Hamodrakas
Vassiliki IconomidouVassiliki Iconomidou
Vassiliki Iconomidou
Protein-protein interactions are the quintessence of physiological activities, but also participate in pathological conditions. Amyloid formation, an abnormal protein-protein interaction process, is a widespread phenomenon in divergent proteins and peptides, resulting in a variety of aggregation disorders. The complexity of the mechanisms underlying amyloid formation/amyloidogenicity is a matter of great scientific interest, since their revelation will provide important insight on principles governing protein misfolding, self-assembly and aggregation. The implication of more than one protein in the progression of different aggregation disorders, together with the cited synergistic occurrence between amyloidogenic proteins, highlights the necessity for a more universal approach, during the study of these proteins. In an attempt to address this pivotal need we constructed and analyzed the human amyloid interactome, a protein-protein interaction network of amyloidogenic proteins and their experimentally verified interactors. This network assembled known interconnections between well-characterized amyloidogenic proteins and proteins related to amyloid fibril formation. The consecutive extended computational analysis revealed significant topological characteristics and unraveled the functional roles of all constituent elements. This study introduces a detailed protein map of amyloidogenicity that will aid immensely towards separate intervention strategies, specifically targeting sub-networks of significant nodes, in an attempt to design possible novel therapeutics for aggregation disorders.

1 August 2015 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
NLNikolaos Louros
Nikolaos Louros
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
MGMichael D.W. Griffin
Michael D.W. Griffin
GHGeoffrey J. Howlett
Geoffrey J. Howlett
SHStavros J. Hamodrakas
Stavros J. Hamodrakas
Vassiliki IconomidouVassiliki Iconomidou
Vassiliki Iconomidou

13 March 2022 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
PSPanagiotis Spatharas
Panagiotis Spatharas
GNGeorgia Nasi
Georgia Nasi
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
MTMarilena Theodoropoulou
Marilena Theodoropoulou
NPNikos Papandreou
Nikos Papandreou
Vassiliki IconomidouVassiliki Iconomidou
Vassiliki Iconomidou
Clusterin is a heterodimeric glycoprotein (α- and β-chain), which has been described as an extracellular molecular chaperone. In humans, clusterin is an amyloid-associated protein, co-localizing with fibrillar deposits in several amyloidoses, including Alzheimer's disease. To clarify its potential implication in amyloid formation, we located aggregation-prone regions within the sequence of clusterin α-chain, via computational methods. We had peptide-analogues, which correspond to each of these regions, chemically synthesized and experimentally demonstrated that all of them can form amyloid-like fibrils. We also provide evidence that the same peptide-analogues can inhibit amyloid-β fibril formation, potentially making them appropriate drug candidates for Alzheimer's disease. At the same time, our findings hint that the respective aggregation-prone clusterin regions may be implicated in the molecular mechanism in which clusterin inhibits amyloid formation. Furthermore, we suggest that molecular chaperones with amyloidogenic properties might have a role in the regulation of amyloid formation, essentially acting as functional amyloids.

1 August 2016 in Journal of Structural Biology
Verified
Journal Article
Closed access
NLNikolaos Louros
Nikolaos Louros
GBGeorgios M.P. Bolas
Georgios M.P. Bolas
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
SHStavros J. Hamodrakas
Stavros J. Hamodrakas
Vassiliki IconomidouVassiliki Iconomidou
Vassiliki Iconomidou

1 September 2015 in Journal of Structural Biology
Verified
Journal Article
Closed access
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
NLNikolaos Louros
Nikolaos Louros
SHStavros J. Hamodrakas
Stavros J. Hamodrakas
Vassiliki IconomidouVassiliki Iconomidou
Vassiliki Iconomidou

9 November 2013 in FEBS Letters
Verified
Journal Article
Closed access
NLNikolaos Louros
Nikolaos Louros
VIVassiliki A. Iconomidou
Vassiliki A. Iconomidou
PTParaskevi Tsiolaki
Paraskevi Tsiolaki
Evangelia ChrysinaEvangelia Chrysina
Evangelia Chrysina
GBGeorgios E. Baltatzis
Georgios E. Baltatzis
SHStavros J. Hamodrakas
Stavros J. Hamodrakas